Pipeline

In addition to the development of NextGen, GenX, and Opt AAV3 vectors for gene therapy of hemophilia in adult patients, sAAVient Therapeutics is also developing novel vectors and strategies to treat children with hemophilia. sAAVient Therapeutics has also identified several human liver diseases in which other AAV serotype vectors have either been shown to be ineffective, or less than optimal.